CStone Pharmaceuticals ( (HK:2616) ) has issued an update.
CStone Pharmaceuticals announced its annual results for the year ended December 31, 2024, reporting a total revenue of RMB407.2 million, which reflects a decrease of 12.2% from the previous year. Despite the decline in revenue, the company significantly reduced its loss for the year to RMB91.2 million, a 75.2% decrease from 2023, primarily due to a substantial reduction in operating expenses, including research and development, administrative, and selling and marketing expenses.
More about CStone Pharmaceuticals
CStone Pharmaceuticals is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative immuno-oncology and precision medicine therapies. The company is listed on the Stock Exchange of Hong Kong and is involved in the sales of pharmaceutical products and licensing activities.
YTD Price Performance: 49.13%
Average Trading Volume: 4,427,842
Technical Sentiment Signal: Sell
Current Market Cap: HK$4.18B
For detailed information about 2616 stock, go to TipRanks’ Stock Analysis page.